Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Clearside Says Uveitis Indication For Xipere Would Keep Company Afloat

Nov 05 2018

• By Emily Hayes

Eye In High Tech Environment

Related Content

Early Yutiq Approval Gives EyePoint Two Ophthalmic Drugs To Launch In 2019

Oct 15 2018

Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?

Jun 17 2013

Related Companies

Clearside Biomedical, Inc.

Regeneron Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc.

Bausch Health Companies Inc.

Allergan plc

Additional Topics

Research & Development Ophthalmic BioPharmaceutical

More from R&D

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window